Volume 123, Issue 4 , Pages 770-771.e1, April 2009
Anti-IgE therapy: Clinical utility beyond asthma
Key words: Omalizumab, Anti-IgE, immunotherapy, rhinitis, urticaria, allergy, food allergy
No abstract is available. To read the body of this article, please view the Full Text online.
Disclosure of potential conflict of interest: T. B. Casale is a consultant for Barofold, Dynavax, Kalobios, and VentiRx; receives research support from Alcon, Allergy Therapeutics, Allied Health International, Amgen, Dynavax, Inc, Greer, Merck, Novartis Pharmaceuticals, Pfizer, Inc, Schering-Plough, Genentech, MedImmune, and BaroFold; is on the board of directors for the World Allergy Organization; and is Executive Vice President of American Academy of Allergy, Asthma, and Immunology. J. R. Stokes is on the speakers' bureau for GlaxoSmithKline.
PII: S0091-6749(09)00339-X
doi:10.1016/j.jaci.2009.02.016
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 123, Issue 4 , Pages 770-771.e1, April 2009
